UT Southwestern Receives FDA Grant To Continue Studies Of Cancer-Fighting Drug Not Used For Past 50 Years

October 17, 1997

DALLAS -- Oct. 16, 1997 -- Success in treating stubborn cancers with a drug that was shelved 50 years ago has encouraged the Food and Drug Administration (FDA) to provide a three-year, $447,534 grant to UT Southwestern Medical Center at Dallas to begin second-stage clinical tests of the drug, aminopterin.

Aminopterin is the "parent" of the commonly prescribed, cancer-fighting drug methotrexate. Originally tested in the 1940s, it fell out of favor with doctors because of concerns about toxicity and difficulties synthesizing it. In recent years, Dr. Barton Kamen, a professor of pediatrics and pharmacology at UT Southwestern, has taken a new look at the drug to see if it might prove effective in treating patients -- particularly children with leukemia -- whose cancer does not respond to methotrexate.

The pediatrician doesn't usually treat adults, but Ingrid Cofield, a 49-year-old woman from Rowlett, Texas, is glad he made an exception.

Cofield was one of several adults Kamen enrolled in a Phase I trial of the drug aminopterin last year.

Phase I trials usually are conducted to see what doses of drugs patients can tolerate. But the aminopterin made a tumor in Cofield's liver disappear.

"I didn't expect this at all," Cofield said. "I thought maybe it would become a little smaller, but not that it would all go away."

Cofield originally was diagnosed with endometrial cancer in 1993. She had a hysterectomy to remove her cancerous uterus and then went through chemotherapy. The cancer was gone for a year, but then she discovered a lump in her groin. Hormonal therapy prevented enlargement for a while, but the lump started growing again. She again underwent chemotherapy, but tests soon showed the tumor had spread to her liver.

Dr. David Scott Miller, an associate professor of obstetrics and gynecology and holder of the Dallas Foundation Chair in Gynecologic Oncology at UT Southwestern, was Cofield's doctor. Knowing of Kamen's aminopterin trial, Miller referred her to Kamen, and Cofield was enrolled in the study.

"I've always been a fighter," said Cofield, who won the women's master's division of the 1988 and 1989 White Rock marathons. "They gave me a choice of going home and living what life I had left or trying the experimental treatment. I said, 'I'd try it.'"

Of the 20 patients who participated in the Phase I trial, three others also showed a positive response to the aminopterin: an 8-year-old boy with a nerve-sheath tumor, a 10-year-old boy with acute-myelogenous leukemia (AML) and a 4-year-old girl with a neuroectodermal tumor.

Kamen presented his findings to the American Society for Clinical Oncology (ASCO) in May.

"This is terrific news for the patients and terrific news for us," said Kamen, holder of the Carl B. and Florence E. King Foundation Distinguished Chair in Pediatric Oncology Research. "In the 20 years I've been doing this, I can't remember this many responses in a Phase I trial. This means we can be optimistic we have an effective drug."

The FDA-funded Phase II clinical trial of the drug is already under way. The first patient enrolled in the trial, which focuses on leukemia patients, is in complete remission.

Four other institutions are participating in the Phase II study: The University of Chicago Division of the Biological Sciences Pritzker School of Medicine, St. Jude Children's Research Hospital in Memphis, UT M.D. Anderson Cancer Center in Houston and UT Health Science Center at San Antonio.

Because of aminopterin's success in Cofield, doctors at UT Southwestern also are beginning a separate clinical trial of the drug on women with persistent or recurrent endometrial cancer.

Cofield, meanwhile, still cannot be considered cured, but Kamen said her complete remission means she is much more likely to be cancer-free in the future.

The aminopterin is made for UT Southwestern by ILEX Oncology of San Antonio.


UT Southwestern Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.